Catalent has signed a collaboration deal with pharma giant Sanofi, lending out its proprietary approach to crafting antibody-guided treatments.
Genomics data provider Metanome and Companion PBx, a company that's developing microbiome-based nutritional products for cats and dogs, have formed a new partnership to develop a sample collection kit and web-based survey, which will be used to build a microbiome database containing information on thousands of healthy and sick dogs.
The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.
Back in January of 2012, Third Rock's upstart epigenetics play Constellation Pharmaceuticals landed a three-year deal with a marquee development partner. Genentech agreed to step in, provided a cash commitment of $95 million to cover part of the Cambridge, MA-based biotech's R&D overhead, and added an option to buy the company. Now the collaboration part of the deal is complete, and on Friday the biotech quietly laid off 23 staffers as it sketched out a path that would allow it to go it alone--if Genentech doesn't acquire the company by its deadline later this year.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.
Philips announced that it will share anonymized data on more than 100,000 patients collected via its Hospital to Home eICU telehealth initiative with the Massachusetts Institute of Technology.
The National Cancer Centre Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration and Singapore's Health Sciences Authority, highlighting the wealthy city-state's push to be a leader in early stage clinical trials in Asia.
As med tech companies home in on next-generation devices for diabetes, researchers are developing a noninvasive temporary tattoo that can monitor glucose levels through the skin.
Belgian drugmaker UCB has inked a $480 million deal to team up with Neuropore Therapies on some early-stage treatments for Parkinson's disease.
Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.